title: Functional characterization and m-RNA expression of 5-HT receptors mediating contraction in human umbilical artery.
abstract: 5-HT1-like and 5-HT2 receptors have both been described to mediate contractions to 5-HT in the human umbilical artery (HUA). However, the nature of the 5-HT receptor subtypes is unknown. 2 In isometric force studies with ring preparations of HUA alpha-methyl-5-hydroxytryptamine (alpha-Me-5-HT) and 5-hydroxytryptamine (5-HT) contracted HUA with pED50 values of 8.04 and 7.74, respectively. In the presence of a subthreshold concentration of another vasoconstrictor sumatriptan and 5-nonyloxytryptamine elicited concentration-dependent contractions with pEC50 values of 7.21 and 7.67, respectively. In the presence of the selective 5-HT1B/D receptor antagonist GR127935, contractile responses elicited by sumatriptan and 5-nonyloxytryptamine were competitively antagonized (pKB 9.01 and 9.02, respectively). In the experiments with 5-HT, GR127935 appeared to be non-competitive with shallow Schild plot slopes. The data were fitted with two linear regression lines and the calculated pKB of the high affinity component (8.90) was comparable to that expected for GR127935 at the 5-HT1B/1D receptor. Several 5-HT2 selective receptor antagonists (spiperone, cyproheptadine, pirenperone) competitively inhibited responses to 5-HT. The selective 5-HT2A antagonist ketanserin against sumatriptan and 5-nonyloxytryptamine behaved as a weak antagonist while against 5-HT demonstrated a competitive antagonism (pKB 8.56). Using specific primers for human 5-HT1B, 5-HT1D and 5-HT2A receptor genes, the reverse transcriptase-polymerase chain reaction revealed mRNA expression of 5-HT1B and 5-HT2A receptors in the HUA. The results suggest that the HUA has a functional population of 5-HT1B and 5-HT2A receptor subtypes which are involved in the contractile response to 5-HT. Contractions mediated by 5-HT1B receptors can be 'uncovered' by exposure to other vasoactive agents.
authors.affiliation: Department of Pharmacology & Therapeutics, Faculty of Medicine, University of Calgary, Alberta, Canada.
authors.forename: F
authors.initials: F
authors.lastname: Lovren
authors.forename: X F
authors.initials: XF
authors.lastname: Li
authors.forename: J
authors.initials: J
authors.lastname: Lytton
authors.forename: C
authors.initials: C
authors.lastname: Triggle
mesh_terms: D006801:Humans; D007650:Ketanserin / Q000494:pharmacology; D010069:Oxadiazoles / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D011985:Receptors, Serotonin / Q000145:classification / Q000235:genetics / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012701:Serotonin / Q000494:pharmacology; D018170:Sumatriptan / Q000494:pharmacology; D014469:Umbilical Arteries / Q000502:physiology*; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D010069:Oxadiazoles; D010879:Piperazines; D012333:RNA, Messenger; D011985:Receptors, Serotonin; C090701:GR 127935; D012701:Serotonin; D018170:Sumatriptan; D007650:Ketanserin; C015068:1-(3-chlorophenyl)piperazine